Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 7:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 327 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: University of Michigan Rogel Cancer Center Clear all
Recruiting Not applicable Interventional

Breast Cancer Resiliency Through Exercise Program (B-REP)

NCT06100263
View directory record Official record
Conditions
Breast Cancer Female
Interventions
Individualized exercise program, Control Arm
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 13, 2026, 7:42 PM EDT
Completed Phase 2 Interventional

Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome

NCT00005598
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
amifostine trihydrate, azacitidine
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 21, 2012 · Synced Oct 13, 2026, 7:42 PM EDT
Completed Phase 2 Interventional Results available

FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)

NCT03556904
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ablative Radiation Therapy, Hormone therapy or chemotherapy
Radiation · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 13, 2026, 7:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer

NCT00645333
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
MK-0752, Docetaxel, Pegfilgrastim
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
3
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2014 · Synced Oct 13, 2026, 7:42 PM EDT
Terminated Not applicable Interventional Results available

Trial Comparing Stereotactic Body Radiation Therapy to Radiofrequency Ablation for Renal Cell Carcinoma

NCT02138578
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
SBRT, RFA
Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Oct 13, 2026, 7:42 PM EDT
Terminated Phase 2 Interventional

Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus

NCT00239200
View directory record Official record
Conditions
Metastatic or Recurrent Squamous Cell Carcinoma of the Esophagus
Interventions
Lapatinib
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 30, 2008 · Synced Oct 13, 2026, 7:42 PM EDT
Terminated Phase 2 Interventional Results available

Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia

NCT00573378
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
PEG-IFN-a2b
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Oct 13, 2026, 7:42 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer

NCT00230399
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Celecoxib, Capecitabine, Irinotecan
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 21, 2015 · Synced Oct 13, 2026, 7:42 PM EDT
Completed Phase 2 Interventional

Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients

NCT02763033
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation
Interventions
Bob's Red Mill®, Starch Placebo
Drug · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
10 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 13, 2026, 7:42 PM EDT
Completed Phase 2 Interventional Results available

Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant

NCT01790568
View directory record Official record
Conditions
Graft vs Host Disease, Hematologic Neoplasms, Non-Neoplastic Hematologic and Lymphocytic Disorder
Interventions
Vorinostat, Tacrolimus, Methotrexate
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Oct 13, 2026, 7:42 PM EDT
Terminated Phase 1 Interventional Results available

A Pilot Study Assessing Intra-Metastasis Administration of Autologous KLH-pulsed Dendritic Cells With Tumoral Radiation Therapy in Patients With Metastatic Pancreatic Carcinoma

NCT00843830
View directory record Official record
Conditions
Metastatic Pancreatic Carcinoma
Interventions
tumoral irradiation, Dendritic cell vaccination
Radiation · Biological
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Oct 13, 2026, 7:42 PM EDT
Terminated Early Phase 1 Interventional

Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy

NCT03208712
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Atezolizumab, Radium-223
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 13, 2026, 7:42 PM EDT
Not yet recruiting Not applicable Interventional

SunBeast: Evaluating UV Protective Behaviors and Education Interventions Among Ultrarunners

NCT07481344
View directory record Official record
Conditions
Sun Protection
Interventions
SunBeast Educational module, Control
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 13, 2026, 7:42 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy

NCT04497038
View directory record Official record
Conditions
Advanced Adult Hepatocellular Carcinoma
Interventions
Cabozantinib
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 13, 2026, 7:42 PM EDT
Completed Not applicable Interventional Results available

Surgical Treatment of Post-surgical Mastectomy Pain Utilizing the Regenerative Peripheral Nerve Interface

NCT04530526
View directory record Official record
Conditions
Post-Mastectomy Chronic Pain Syndrome
Interventions
Regenerative Peripheral Nerve Interface
Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 13, 2026, 7:42 PM EDT
Terminated Phase 1 Interventional Results available

Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer

NCT01642732
View directory record Official record
Conditions
Prostate Cancer
Interventions
Everolimus, lupron, bicalutamide, and radiation
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 13, 2026, 7:42 PM EDT
Completed Not applicable Interventional

CLEAR Care Companion Application

NCT05578898
View directory record Official record
Conditions
Bladder Cancer, Radical Cystectomy
Interventions
CLEAR Care Companion (CC) application
Behavioral
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 13, 2026, 7:42 PM EDT
Terminated No phase listed Observational Results available

Pilot Study of dMRI as a Tool for Early Evaluation of Tumor Response in Diffuse Large B-cell Lymphoma

NCT00645359
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma
Interventions
diffusion MRI
Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 14, 2017 · Synced Oct 13, 2026, 7:42 PM EDT
Completed Not applicable Interventional

Feasibility and Evaluation of a Self-care App to Enhance Purposeful Living

NCT04458168
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Use of Purposeful app
Behavioral
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Oct 13, 2026, 7:42 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone

NCT01428219
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
Cabozantinib
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 13, 2026, 7:42 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)

NCT02663622
View directory record Official record
Conditions
Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation, Leukemia
Interventions
Efprezimod alfa, Methotrexate, Tacrolimus, Placebo
Drug
Lead sponsor
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
4
States / cities
Indianapolis, Indiana • Ann Arbor, Michigan • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Oct 13, 2026, 7:42 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

NCT02677948
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
Interventions
Pacritinib, Ibrutinib
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Ann Arbor, Michigan • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Oct 13, 2026, 7:42 PM EDT
Completed Phase 2 Interventional Results available

Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer

NCT03829722
View directory record Official record
Conditions
Oropharynx Squamous Cell Carcinoma
Interventions
Nivolumab, Carboplatin, Paclitaxel, Radiation Therapy
Drug · Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 13, 2026, 7:42 PM EDT
Completed Not applicable Interventional Results available

A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer

NCT02492867
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Response-driven Adaptive Radiation Therapy, Carboplatin, Paclitaxel, FDG-PET, V/Q SPECT, Durvalumab
Radiation · Drug · Device
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 13, 2026, 7:42 PM EDT